Innohep (Tinzaparin Sodium)

• Innohep, a low molecular weight heparin, acts on the venous thrombo‑embolism pathway to reduce clot formation.
• Deep Vein Thrombosis: prevents clot formation and treats existing thrombi in the deep veins.
• Pulmonary Embolism: reduces the risk of embolic events and treats established pulmonary emboli.
• Post‑operative Patients: prevents venous thrombo‑embolism after surgical procedures.

• Tinzaparin sodium binds to antithrombin III, enhancing its ability to inhibit factor Xa and, to a lesser extent, thrombin (factor IIa). This accelerated inhibition disrupts the coagulation cascade, decreasing fibrin formation and limiting clot propagation.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects

• Injection site pain or erythema
• Minor bruising or hematoma at the injection site
• Mild gastrointestinal upset
• Transient headache
• Nausea
• Slight elevation of liver enzymes

Serious or Rare Side Effects

• Major bleeding (intracranial, gastrointestinal, or retroperitoneal)
• Heparin‑induced thrombocytopenia (HIT)
• Allergic or anaphylactic reactions
• Spinal or epidural hematoma
• Severe thrombocytopenia unrelated to HIT
• Paradoxical thrombosis (e.g., skin necrosis)

• Use of Innohep requires careful clinical assessment.
• Assess renal function: adjust or avoid in severe renal impairment.
• Monitor platelet count: watch for heparin‑induced thrombocytopenia.
• Evaluate bleeding risk: contraindicated in active major bleeding.
• Use caution with concurrent anticoagulants: increased bleeding potential.
• Avoid in patients with known hypersensitivity to low molecular weight heparins.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium may interact with several medicines that affect coagulation.

Major Interactions (Avoid)

• Concomitant unfractionated heparin
• Simultaneous warfarin during initial therapy
• Direct oral anticoagulants (e.g., apixaban, rivaroxaban)
• Thrombolytic agents (e.g., alteplase)
• High‑dose antiplatelet agents in high‑bleeding‑risk patients

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs)
• Selective serotonin reuptake inhibitors (SSRIs) or SNRIs
• ACE inhibitors in patients with renal impairment
• Diuretics that may alter renal clearance
• Chemotherapy agents causing thrombocytopenia